|
Vertebral Axial Decompression Therapy is an emerging
technology that addresses the biomechanical aspects of
discogenic disease and it should be utilized in patients
with low back pain, with or without radiculopathy, and
should be routinely utilized prior to considering
surgery. By addressing the altered biomechanics
responsible for disc disease, the VAX-D Therapeutic
Table not only alleviates pain but has shown to exert a
beneficial effect on a major determinant in the equation
responsible for discogenic disease, that is elevated
intradiscal pressure.
Chronic back pain patients (and their disability) and
surgical patients are very costly to society. Since
approximately 70% of these patients are responsive to
VAX-D therapy, this unique non-obtrusive means of
managing the common forms of debilitating low back pain
associated with discogenic disease could represent a
considerable economic benefit.
VAX-D is currently being
prescribed and provided in the United States and also in
Canada, Mexico, Puerto Rico and Australia, in clinics
specializing in Neurosurgery, Orthopedics, Neurology,
Physiatry, Pain Management, and in Low-back Pain centers
operated by General Physicians and Doctors of
Osteopathy. In these centers, VAX-D has been adopted as
the primary conservative treatment for the management of
discogenic disease. More than 3000 patients a day now
receive VAX-D therapy in the US. Studies on the efficacy
from all of our independent sources (hospitals, private
clinics, clinical studies) consistently report similar
levels of success in the range of 50-70%.
|
|
